Cardiovascular disease is a group of disorders of the heart and blood vessels. Building on Sanofi’s legacy of more than 60 years of fighting cardiovascular disease, we deliver innovative therapeutic solutions for cardiovascular conditions to people at high risk for cardiac events (such as a heart attack) and who need additional treatment options beyond currently available medications.
Impacts of disease to Australian livesCardiovascular disease and associated risk factors significantly affect people’s quality of life and that of their families, and put a rising medical and economic burden on health systems worldwide.¹
Heart disease alone is the single leading cause of death in Australia: in 2017, almost 19,000 persons died from heart disease, with a further 1,250 deaths from ischaemic stroke. As a risk factor for both diseases, a large proportion of the burden associated with these diseases can be attributed to high cholesterol, also known as hypercholesterolaemia. There are an estimated 7.1 million Australians living with hypercholesterolaemia. This includes those individuals with measured high total cholesterol and those that self-reported as having high cholesterol. Reducing hypercholesterolaemia offers the potential for significant health and economic benefits.²